Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. (15th August 2020)

• Record Type: Journal Article
• Authors: Gniffke, Edward P; Harrington, Whitney E; Dambrauskas, Nicholas; Jiang, Yonghou; Trakhimets, Olesya; Vigdorovich, Vladimir; Frenkel, Lisa; Sather, D Noah; Smith, Stephen E P
• Is Part Of: Journal of infectious diseases. Volume 222:Number 12(2020)
• Page Start: 1965
• Page End: 1973
• Publication Date: 2020-08-15
• Subjects: serology -- COVID-19 -- SARS-COV-2 -- ACE2 -- Spike protein -- binding inhibition -- neutralization; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa508
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin-converting enzyme 2. Plasma from 22 patients who had recovered from mild coronavirus disease 2019 (COVID-19) and expressed anti–spike protein trimer immunoglobulin G inhibited angiotensin-converting enzyme 2–spike protein binding to a greater degree than controls. The degree of inhibition was correlated with anti–spike protein immunoglobulin G levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of patients recovered from COVID-19 or vaccine recipients in a cell-free assay system. Abstract : Using a rapid, microsphere-based assay, the authors quantified the ability of coronavirus disease 2019 convalescent plasma to inhibit binding of severe acute respiratory syndrome coronavirus 2 spike protein to its receptor, angiotensin-converting enzyme, demonstrating inhibition in >90% of recovered patients.